RSS

Patheon

OSD forms are the most common dosage forms and the preferred option for many pharmaceutical products. In this Q&A we speak with Sanjay Konagurthu — Patheon, part of Thermo Fisher Scientific — about this sector. more

Opinion

Findings from a modelling study performed by Tufts Center for the Study of Drug Development (CSDD) have revealed there are financial benefits of using single-source outsourcing partners versus a multivendor development and manufacturing model. more

News

In this article Steve Lam, senior vice president and head of biologics, Patheon, looks at which choice is best when developing a biomanufacturing strategy. more

Opinion

Thermo Fisher Scientific has announced the completion of its acquisition of Patheon, contract development and manufacturing organisation (CDMO) for the pharma and biotech sectors, for approximately $7.2 billion. more

News

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more

News

Global provider of drug development and delivery solutions to the pharmaceutical sector, Patheon, has revealed it is anticipating to invest approximately $45 million at key sites worldwide to meet growing customer demand more

News

An agreement between Fortress Biotech subsidiary, Caelum Biosciences, and Patheon has been made that will involve the process development and cGMP production of CAEL-101 more

News

Global provider of drug development and delivery solutions to pharma and biopharma sectors, Patheon, has announced the completion of its expansion project at its Greenville site in North Carolina. more

News

Stephen Closs, VP, Global Technical Operations, Patheon explains continuous manufacturing as an enabling technology for quality by design – and highlights five ways it adds value for the pharmaceutical industry. more

News

Anil Kane, Ph.D., MBA, executive director, global head of formulation sciences, pharmaceutical development services at Patheon on finding the right formulation for oral solid dose applications more

News

Michael Lehmann, executive vice president, global sales & marketing, Patheon shares his views on the challenges ahead for the pharma sector and how they could mean greater opportunities ahead for pharmaceutical manufacturers more

Opinion

Patheon explains the importance of mergers and acquisitions as the company strengthens its position in the sector. more

Opinion

Spotlight on innovation more

News

Patheon, a provider of high-quality drug development and delivery is to acquire IRIX Pharmaceuticals, a company that specialises in difficult to manufacture Active Pharmaceutical Ingredient (API) needs. more

News

EPM speaks to the team at Quick to Clinic, an initiative offered by Patheon. more

Technology

Following the transaction, Patheon’s biologic drug substance business will span four facilities in Europe, Australia and North America. more

Patheon’s Harry Gill, Senior Vice President, Quality and Continuous Improvement, will be presenting ‘Transforming Quality Performance Using Common Operational Excellence Tools’ at INTERPHEX, 19 March, 3:15 pm, stage 2. more

Technology

CDMO Patheon is increasing solid dose capabilities at its European sites. The latest investments are being made at the company’s Milton Park, UK, facility. This standalone early development centre will now offer automated capsule filling... more

Technology

Patheon’s Harry Gill, SVP, Quality and Continuous Improvement, will present 'Utilising Operational Excellence Principles to Drive Quality Improvements' on Wednesday 23 October at 2:30 p.m., CET on Stand 42L52. more

News